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S U M M A R Y
Objectives: To evaluate the evolution of antibody avidity andWestern blot reactivity in recently infected
HIV-1 subjects and to study the impact of highly active antiretroviral therapy (HAART) on avidity
maturation of HIV-1-speciﬁc immunoglobulin G (IgG) in patients with recent HIV-1 infection.
Methods: Thirty-six HIV-1 seroconverters were enrolled in this study and followed longitudinally over
24 months to evaluate if the administration of antiretroviral therapy during primary infection affects
Western blot reactivity and the evolution of antibody avidity. The patients were divided into two groups;
group A consisted of 19 HIV-1-untreated patients who did not receive any drug treatment during our
follow-up period; group B consisted of 17 subjects who were treated early with an association of two
nucleoside reverse transcriptase inhibitors (NRTI) and one non-nucleoside reverse transcriptase
inhibitor (NNRTI) within 3 months after seroconversion.
Results: At diagnosis, Western blot analysis and avidity index (mean value) were exactly matched in
untreated and treated patients; subsequently, however, a signiﬁcantly lower reactivity to HIV-1 pol and
gag proteins and a lower avidity index (mean values) were observed in HAART-treated patients up until
the end of the follow-up period.
Conclusions: The impaired production and maturation of the humoral immunological response in
antiretroviral-treated patients might be related to a rapid suppression of HIV replication, driven by
HAART. These results could have important implications in understanding the complex mechanism of
the immune response during HIV infection.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The diagnosis of HIV in adults is routinely performed using
serological tests able to detect speciﬁc antibodies to the virus.1
During recent years, serological tests have evolved rapidly, with
combined antigen and antibody tests reaching high levels of
sensitivity for the detection of primary infections.2,3 Despite the
introduction of new generation assays, it is difﬁcult to differenti-
ate recent and long-standing infections, even though this
information may be crucial to establish the incubation period
and for partner notiﬁcation, epidemiological surveillance, and
patient management.4–6
One approach to identifying recent infections is the investiga-
tion of the level of antibody avidity, as routinely used for several
infectious diseases, such as rubella, cytomegalovirus and Toxo-
plasma gondii infections.7–9* Corresponding author. Tel.: +39 0 51 4290900; fax: +39 0 51 307397.
E-mail address: mariacarla.re@unibo.it (M.C. Re).
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approach affects antibodymaturation or is related to seroreversion
or decreased HIV-1 antibody titers,10–19 although early antiretro-
viral treatment during primary HIV infection might block the
formation of HIV-1-speciﬁc antibodies, leading to a rapid
reappearance upon cessation of therapy.19
Even though several approaches identify acute seroconverters,
including detuned assay, BED-CEIA assay, avidity assays, IDE-V3
assay, IgG3, anti-HIV and Inno-LIA HIV adaptation tests20,21 up to
now all these assays are not yet well standardized and performed
on an in-house basis.
To evaluate the evolution of antibody avidity and Western blot
reactivity over time, we undertook a retrospective study in two
groups of recently seroconverted patients; the ﬁrst group
consisting of patients whowere not treated during our observation
period (untreated HIV) was compared with a second group of
subjects who were treated within 3 months after seroconversion
(treated with highly active antiretroviral therapy (HAART)).
Avidity tests were performed after guanidine serum pre-
treatment, as previously described22 and were analyzed using ases. Published by Elsevier Ltd. All rights reserved.
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lands). Avidity index results were correlated to immunological and
virological parameters from time of diagnosis until the end of the
follow-up period.
2. Materials and methods
2.1. Patients and sera
Serum samples from 36 HIV-1 seroconverters attending
the infectious disease outpatient clinic between February 2005
and October 2007 were enrolled in this study; informed consent
was obtained according to the Helsinki Declaration of 1975.
Intensive medical evaluation established that transmission had
occurred by sexual contact in all subjects, excluding any drug
abuse.
All selected patients met the following criteria: (1) a ﬁrst
indeterminate or positive enzyme-linked immunosorbent assay
followed by Western blot proﬁle compatible with ongoing
seroconversion; (2) a previous conﬁrmed-negative test for HIV
antibody carried out a maximum of 6 months before the ﬁrst
positive test; (3) detectable HIV-1 RNA plasma levels.
The patients were divided into two groups. The ﬁrst group
(group A) comprised 19 untreated HIV-1 patients who did not
receive any drug treatment during our follow-up period, since
they did not meet the criteria for a therapy regimen or had
refused any drug treatment. The second group (group B) included
17 subjects treated early with an antiretroviral combination (two
nucleoside reverse transcriptase inhibitors (NRTI) and one non-
nucleoside reverse transcriptase inhibitor (NNRTI)) within 3
months after seroconversion, following HIV guidelines (http://
aidsinfo.nih.gov/contentﬁles/AdultandAdolescentGL.pdf). The
two groups were matched for age and sex, sharing a similar
gender composition (15 men and four women in group A; 13men
and four women in group B) and mean age (34  9 years in group
A; 36  4 years in group B) (Table 1). All patients were followed
longitudinally over 24 months; plasma and serum samples were
collected at time 0 (ﬁrst positive serum) and at 6, 12, 18, and 24
months thereafter. Longitudinal serum and plasma samples were
stored at 20 8C until use and tested by immunoblot assay and
guanidine-based avidity assay, and for RNA viral load and CD4
count.
2.2. ELISA and immunoblot assay
Each sample was tested by ELISA (Vironostika; BioMe´rieux,
Boxtel, the Netherlands) and immunoblot (INNO-LIATM HIV-1/2
Score Assay; Innogenetics, Ghent, Belgium) according to the
manufacturers’ instructions. Immunoblot strips were inter-
preted following the criteria of the INNO LIA HIV-1/2
score test and read and interpreted by LiRASTM software; the
intensity of the antibody response to speciﬁc HIV-1/2 proteins
spotted on the ﬁlter is analyzed by scanner and compared with
an internal control. The software describes the intensity
strength with a value ranging from 4+ to . We considered aTable 1
Baseline characteristics of HIV-1-positive patients (group A: untreated HIV
subjects; group B: HIV subjects treated early) enrolled in the study.
Group A Group B
Number of patients 19 17
Gender 15M and 4 F 13M and 4 F
Age, years (mean SD) 349 364
CD4+T-cell count, cell/ml (mean SD) 66810 391150
RNA viral load, copies/ml (mean) 1104 2.7104
M, male; F, female; SD, standard deviation.line positive when the intensity of the antigen–antibody reaction
was between 2+ and 4+.
2.3. HIV antibody avidity assay
For each serum sample, two aliquots were prepared, one by a 1/
10 dilutionwith phosphate-buffered saline (PBS) and onewith 1 M
guanidine (G) as denaturing agent. Both aliquots were shaken and
incubated for 10 min at room temperature and then tested as
previously described21,22 using the Vironostika ELISA platform
(BioMe´rieux). Sample to cut-off ratios (S/CO) were calculated and
the avidity index of HIV antibodies was computed as (S/CO of the G
aliquot)/(S/CO of the PBS aliquot). A cut-off of 0.75 was selected
according to previous observations.19,21,22
2.4. HIV-1 RNA quantiﬁcation
The quantiﬁcation of HIV-1 RNA viral load was carried out by
Quantiplex HIV-RNA 3.0 assay (Siemens, Munich, Germany)
according to the manufacturer’s instructions.
2.5. Peripheral blood CD4 lymphocytes
Peripheral blood CD4 + T lymphocytes were counted by ﬂow
cytometry (FACScan; Becton and Dickinson, Mountain View, CA,
USA) using commercially available monoclonal antibody (Becton-
Dickinson).
2.6. Statistical analysis
Simple descriptive statistical measures for the avidity index
were calculated (median and range). Fisher’s test and theWilcoxon
rank sum test were used for immunoblot and avidity index results,
respectively.
3. Results
3.1. Immunoblot assay
Antibody patterns were studied by immunoblot analysis in all
serum samples from time 0 (ﬁrst positive serum) onwards. As
discussed in the Materials and methods, we considered the
antibody response to speciﬁc HIV protein to be positive when the
intensity of the antigen line reaction was between 2+ and 4+
positive rating, validated by software comparison with positive
and negative control strips. The speciﬁc HIV-1 proteins used as
targets in the INNO-LIA system are the gp120, gp41, p31, p24 and
p17 viral proteins.
Thepercentageof serumreactivity (from2+to4+ rating) toHIV-1
proteinswas similar in the two groups of patientswhen the analysis
was performed at time 0 (Fig. 1), showing a comparable percentage
of sera that reacted to env glycoprotein gp120 (84% group A vs. 76%
group B, p = 0.7), to env glycoprotein gp41 (100% in both groups of
patients analyzed), to pol protein p31 (52% group A vs. 47% group B,
p = 1.0), togagproteinp24 (68%groupAvs. 70%groupB,p = 1.0), and
to gag protein p17 (63% group A vs. 58% group B, p = 1.0).
By contrast, subsequent analyses at later times (from 6 months
onwards) showed a signiﬁcantly lower reactivity to HIV-1 pol and
gag proteins in HAART-treated patients (Fig. 1). In particular,
among treated patients (group B) at 6months after seroconversion,
only seven reacted to p31 (41% vs. 94%; p = 0.00), 12 to p24 (70% vs.
94%; p = 0.08), and 10 to p17 (58% vs. 89%; p = 0.05). This lower
reactivity persisted throughout the observation period, showing
signiﬁcantly low levels of antibody to p31 (p < 0.01 at 12, 18 and
24 months), to p24 (p < 0.01 at 12, 18 and 24 months), and to p17
(p < 0.01 at 12, 18 and 24 months).
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Fig. 1. Reactivity to env (gp120 and gp41), pol (p31), and gag (p24 and p17) proteins in untreated (top) and early treated (bottom) HIV-1 patients, from certiﬁed infection (0
months) onwards (6, 12, 18 and 24 months).
[(Fig._2)TD$FIG]
Fig. 2. Evolution of antibody avidity (expressed as avidity index) from time 0
(certiﬁed infection) onwards (6, 12, 18 and 24 months) in (A) untreated HIV-1
patients and (B) HIV-1 patients treated with HAART (within 3 months of
seroconversion).
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At diagnosis (time 0), the mean avidity index value was
absolutely matched (p = 0.83) in untreated (OD values ranging
from 0.2 to 0.72; avidity index mean 0.51  0.15) and treated (OD
from 0.3 to 0.7; avidity indexmean 0.50  0.13) patients. Among sera
analyzed at later times, a clear difference in the mean avidity index
values between treated and untreated patientswas already evident at
6 months, with avidity index values in treated patients lower than
those observed in untreated patients (0.66 vs. 0.8, p = 0.03). Similarly,
the difference was signiﬁcant up to the end of the observation period
(0.74 vs. 0.92, p = 0.001 at 12 months; 0.79 vs. 0.98, p = 0.000 at 18
months; 0.90 vs.1.00, p = 0.00 at 24 months) (Fig. 2).
Even though individual variability in the rapidity of avidity
maturation exists and different avidity index cut-offs (a
conservative cut-off <0.75 (Chawla et al.6) or more conventional
cut-off <0.8 (Suligoi et al.5)) have been proposed for the
antibody avidity assay to identify ‘recent infection’, our results
show that most (82%) early treated patients had a low avidity
index value (ranging from 0.5 to 0.7 OD) in comparison to
untreated patients (26%).
3.3. HIV-1 RNA viral load and CD4 levels
The overall viral load at baseline showed a lower (p = 0.07)
mean value in naı¨ve individuals (mean value 1  104 copies/ml) in
comparisonwith treated individuals (mean value 2.7  104 copies/
ml). As expected, constant high levels of RNA viral load (3.7  104,
5.3  104, 3.2  104 and 6.8  104 HIV-1 RNA copies/ml at 6, 12, 18
and 24 months, respectively) were observed in untreated patients,
whereas a signiﬁcant decrease was observed from 6 months
onwards following antiretroviral treatment (4.5  102, 6.4  101,6.1  101 and less that 50 HIV-1 RNA copies/ml at 6, 12, 18 and 24
months, respectively).
CD4 cell counts (cell/ml) tended to be higher in untreated
patients than treated patients at 0 and 6 months of observation
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months, p < 0.01). No signiﬁcant differences were found thereafter
(665  141 vs. 641  435 at 12 months; 659  184 vs. 689  668 at
18 months, and 647  182 vs. 825  551 at the end of observation
period; p = 0.8, 0.85 and 0.2, respectively). However, the CD4 follow-
up conﬁrmed a constant trend in untreated subjects (p > 0.5) and a
signiﬁcant recovery of CD4 following antiretroviral treatment
(p = 0.04).
4. Discussion
This study reports a longitudinal retrospective analysis of
immunological and virological parameters detected in 36 selected
HIV-positive patients with recent seroconversion. The progression
of HIV infection was followed in these patients for 2 years to
determine the evolution of antibody avidity and Western blot
reactivity in recently infected HIV-1 subjects and to study the
impact of HAART on avidity maturation of HIV-1-speciﬁc
immunoglobulin G (IgG) in patients with recent HIV-1 infection.
Our results show an impaired production andmaturation of the
humoral immunological response in patients treated early with
HAART, as demonstrated by low levels of antibody to pol and gag
proteins detected by immunoblot and low avidity levels conﬁrmed
by a lower index at 6 months (0.66 vs. 0.8, p = 0.03, treated vs.
untreated patients). In particular, most early treated subjects (82%)
showed a low avidity index value (ranging from 0.5 to 0.7 OD) in
comparison to untreated patients (26%).
Several reports on this topic15,17–19,24 have given rise to lively
debate on the impact of antiretroviral treatment on antibody
maturation. HAART appears to prevent the emergence of IgG
antibodies, since HIV replication elicits the production of anti-HIV
antibodies directly, through the persistent production of stimulat-
ing antigens, or indirectly, through the release of cytokines
stimulating B-lymphocytes such as interleukin-6 (IL-6) and
interferons (IFN).15,23
We found that treated patients developed a complete
immunoblot response only to envelope proteins (HIV-1 gp120
and gp41) within 6 months and only a limited number of patients
showed a high reactivity to pol and gag proteins. At 6 months only
41% of HAART-treated patients showed a detectable presence of
antibody to p31, whereas most untreated patients (94%) reacted to
p31. In addition, a signiﬁcant difference in the immunologic
response to p31 and to gag viral proteins p24 and p17 was also
observed at later times (12–24months) in HAART-treated patients.
On the other hand, Selleri and coworkers19 showed that antibody
to HIV-1 reached a complete repertoire 6 months after diagnosis in
most treatedpatients (sevenout eight subjectsenrolled in the study)
and in only one later on (within 10 months). This relative
discrepancy may be related to several factors, such as the length
of follow-up period, elevated individual variability, the speciﬁc
HAARTcombinationused, and the serological techniques employed.
Besides the low or slow IgG maturation process, we also found
that early institution of HAART prevents the gradual evolution of
the avidity index of HIV-1-speciﬁc antibodies. Our results are in
agreement with the data of several authors17,19,24,25 who have
demonstrated not only the relationship between viral suppression
established by HAART and low antibody avidity, but also the
increase in avidity index values after discontinuation of HAART
therapy.19
In addition, studies by other authors15,19 on a limited but
suggestive number of HAART-treated patients have failed to show
any difference in IgGmaturation (as demonstrated byWestern blot
and avidity index) in NNRTI or protease inhibitor (PI)-treated
patients.
Moreover, not all data concerning the low response to someHIV
proteins and the low avidity index levels can be explained in termsof CD4 counts: although the CD4 cell count tended to be higher in
untreated patients at 0 and 6months of observation, no signiﬁcant
differences were found thereafter. Moreover, the signiﬁcant
increase in CD4 levels in patients seems to be exclusively related
to antiretroviral therapy leading to a CD4 recovery. However a
careful evaluation of serological and immunological markers is
necessary to fully characterize the course of HIV-1 infection and to
provide a more complete laboratory-based assessment of disease
progression.
Even though the role of the avidity index as amarker to evaluate
the use of HAART in acute or early HIV infection or to predict
treatment outcome remains unknown, our results have at least
two major implications. First, the altered kinetics of the avidity
index, often used in seroepidemiological studies to determine the
approximate time of infection, is probably related to early control
of viremia during HAART and could lead to inconsistent estimates
in a substantial proportion of patients. Second, our data add new
information on the complexity of the initial host–virus interaction
during primary HIV infection.
Themechanisms underlying the low antibody response (both in
terms of antibody maturation to single viral proteins and levels of
avidity index) remain undetermined. However, some studies have
demonstrated an IFN type I production defect during the course of
primary HIV infection, suggesting a severe impairment in anti-HIV
antibody production in recently converted patients.23
In particular, since HIV replication stimulates HIV antibody
directly by a persistent production of antigens and indirectly by the
release IL-6 and IFN able to stimulate B lymphocytes, the
impairment of both types of cytokine due to antiretroviral therapy
might also explain why HAART could be responsible for a reduced
amount of HIV antibody.15
In addition, the different pharmacological combinations used to
switch off viral replication could play a role in the humoral
response, determining a different impairment in antibody afﬁnity
maturation. In fact, afﬁnity maturation of the humoral immune
response is regulated by antigen somatic hypermutation (SHM) of
the genes encoding immunoglobulin variable regions, with the
subsequent antigenic selection of mutant B clones. DNA hyper-
mutagenesis at dC/dG and dA/dT pairs is linked to DNA
polymerase-u and DNA polymerase-h, which are partially
inhibited by nucleoside analysis.26 Hence, afﬁnity maturation
and isotype switching may be more or less damaged by different
therapeutic associations.
In vitro studies to verify the B-lymphocyte response to single
drugs (both reverse transcriptase and protease inhibitors) are in
progress, to study the effect of single or associated drugs on B cell
maturation and their capacity for antibody production. However,
in a complex scenario also characterized by the so-called ‘late
presenters’, the importance of diagnosing HIV infection at an early
stage is unquestionable. Besides all the public health implications,
the distinction between recent and chronic infection might serve
to establish the time of infection and therefore allow any potential
partners who could have been infected during a speciﬁc period of
time to be reached.
Although results based on avidity index in patients who
started therapy early may represent a limitation to this objective,
the routine application of methods able to distinguish recent
from long-lasting infection might have great impact on public
health in monitoring disease incidence, in identifying high-risk
groups, and in enhancing epidemiological conclusions. Lastly, as
standardization of the test used is one of the most important
points for test results to be clinically signiﬁcant, all the data
available on this topic suggest indications on the method and its
applicability, even if its utility will depend on operating
characteristics, HIV-1 subtype limitations, and selection of
appropriate assay cut-off values.
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